01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billiona, up 23% year-over-year.
This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22b, reflecting improved operational efficiency and strategic asset contributions.
However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billionc from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.
02—Key points
Key Highlights
- Total revenues increased by 23% to $8.5 billion for the third quarter of 2024, compared to $6.9 billion in the prior year period.
- Product sales surged by 24% to $8.15 billion, driven by strong volume growth and contributions from acquired Horizon Therapeutics products.
- Net income increased by 64% to $2.83 billion, with diluted Earnings Per Share (EPS) rising to $5.22 from $3.22 in the prior year quarter.
- Operating expenses rose by 32% to $6.46 billion, primarily due to increased amortization from acquisition-related assets, R&D, and SG&A expenses.
- Cash and cash equivalents decreased to $9.01 billion as of September 30, 2024, from $10.94 billion as of December 31, 2023, impacted by debt repayment and dividend payments.
- The company is actively managing its debt, with significant repayments and extinguishments during the first nine months of 2024.
- Amgen continues to face and disclose significant legal and tax contingencies, notably the ongoing IRS tax dispute, which could materially impact future financial results.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Amgen Inc kept $0.33.
- Revenue$8.50B100.0%
- Cost of revenue−$3.31B38.9%
- Gross profit$5.19B61.1%
- Operating costs−$3.15B37.0%
- Operating income$2.05B24.1%
- Interest, other & tax$783.0M9.2%
- Net income$2.83B33.3%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $8.50B$6.90B | +23.2% |
| Cost of Revenue | $3.31B$1.81B | +83.3% |
| Gross Profit | $5.19B$5.10B | +1.9% |
| SG&A Expenses | $1.63B$1.35B | +20.1% |
| Operating Expenses | $6.46B$4.88B | +32.2% |
| Operating Income | $2.05B$2.02B | +1.3% |
| Interest Expense | $776.00M$759.00M | +2.2% |
| Net Income | $2.83B$1.73B | +63.6% |
| EPS (Basic) | $5.27$3.23 | +63.2% |
| EPS (Diluted) | $5.22$3.22 | +62.1% |
| Shares Outstanding (Basic) | 537.00M535.00M | +0.4% |
| Shares Outstanding (Diluted) | 542.00M538.00M | +0.7% |
05—Questions
Frequently Asked Questions
What drove the significant revenue growth in the third quarter?
Revenue growth was primarily driven by a 24% increase in total product sales, reaching $8.15 billion. This was fueled by strong volume growth across key products and the successful integration of products acquired from Horizon Therapeutics, notably TEPEZZA and KRYSTEXXA. Acquired Horizon products contributed $1.1 billion to product sales in the quarter.
Why did operating expenses increase significantly, and what is the impact on profitability?
Operating expenses increased by 32% to $6.46 billion. This rise is largely attributed to higher amortization expenses related to assets acquired in the Horizon transaction, along with increased spending on research and development and selling, general, and administrative activities. While revenue growth outpaced expense growth in the quarter, leading to a significant net income increase, investors should monitor the sustainability of this margin improvement given the ongoing expense pressures.
What is the status of Amgen's tax dispute with the IRS?
Amgen is actively contesting IRS claims related to profit allocation between its U.S. and Puerto Rico entities for the years 2010-2015. The IRS is seeking substantial additional federal tax, plus interest and penalties. The consolidated trial for the 2010-2012 and 2013-2015 periods is scheduled to begin in November 2024. Amgen believes its tax accruals are appropriate but acknowledges that an adverse outcome could materially impact its financial statements.
How is Amgen managing its debt and capital structure?
Amgen repaid $3.6 billion and extinguished $659 million in debt during the first nine months of 2024. The company also declared quarterly cash dividends of $2.25 per share. While cash and cash equivalents have decreased, Amgen believes its existing funds, cash generated from operations, and access to financing are adequate to meet its obligations, including debt service, capital expenditures, dividends, and potential strategic initiatives.
06—Continue